92 results
D
DMAC
DiaMedica Therapeutics Inc.
2 Jul 24
$11.80 mm in equity, sold $11.80 mm, 10 investors
4:07pm
or due to the nature of the offering that is the subject of this Form D, States cannot
routinely require offering materials under this undertaking … or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
8-K
EX-10.1
DMAC
DiaMedica Therapeutics Inc.
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
in Section 3.1(uu).
“GAAP” shall have the meaning ascribed to such term in Section 3.1(h).
“Hazardous Materials” shall have the meaning ascribed … was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
8-K
EX-10.2
DMAC
DiaMedica Therapeutics Inc.
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
materials in accordance with this Section 3(a).
(b) (i) Prepare and file with the Commission such amendments, including post-effective amendments
DEFA14A
DMAC
DiaMedica Therapeutics Inc.
4 Apr 24
Additional proxy soliciting materials
6:06am
Definitive Additional Materials
☐ Soliciting Material under §240.14a-12
DiaMedica Therapeutics Inc.
(Name of Registrant as Specified In Its Charter … Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
8-K
EX-10.1
t50pfk6g52
5 Sep 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.2
ue49v e1thz35i
5 Sep 23
Departure of Directors or Certain Officers
4:15pm
D
kzdpcfn
27 Jun 23
$37.54 mm in equity, sold $37.54 mm, 34 investors
4:11pm
8-K
EX-10.1
ag82rxdpek uno
21 Jun 23
DiaMedica Therapeutics Announces $37.5 Million Private Placement
8:42am
8-K
EX-10.2
11qss7e0
21 Jun 23
DiaMedica Therapeutics Announces $37.5 Million Private Placement
8:42am
8-K
EX-99.1
b6ow6b1249iev637w8l3
15 May 23
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
4:31pm
D
a6xpoxs9hp4
18 Apr 23
$750.00 k in equity, sold $750.00 k, 1 investor
4:30pm
DEFA14A
jwbyr
4 Apr 23
Additional proxy soliciting materials
7:03am
8-K
EX-99.1
9hhfqvqss
9 Nov 22
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
a6jt5kihgkyhi0d1yl
26 Oct 22
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
4:30pm
8-K
EX-99.1
ifx4n
6 Jul 22
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
4:30pm